MedTrace Logo

GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis

NCT01201135 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2010-09-14

No results posted yet for this study

Summary

Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin with subsequent secondary iron overload.The aim of our present study is to asses the levels of GDF15 and hepcidin in patients with Sickle cell disease and hereditary spherocytosis

Conditions

  • Patients With Thalassemia Intermedia,
  • Congenital Dyserythropoietic Anemia Type I

Sponsors & Collaborators

  • Wolfson Medical Center

    lead OTHER_GOV

Principal Investigators

  • GHOTI HOSSAM, doctor · HEMATOLOGY DEPARTMENT ON WOLFSSON MEDICAL CENTER

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01201135 on ClinicalTrials.gov